MIGS is an innovative approach combining glaucoma treatment with cataract surgery, utilising advanced techniques to control intraocular pressure through tiny incisions and microscopic implants. After successfully launching MIGS at a small number of its hospitals as part of a trial earlier in the year, CHEC is now expanding the service on behalf of the NHS to its sites in Stockport, Stoke, Sheffield, Newcastle, Warrington, Trafford, Ilford, Swindon, and New Cross, with more locations coming soon.

MIGS aims to avoid optic nerve damage and vision loss by addressing blockages at different pressure points in the eye, to enhance natural fluid drainage. By minimising these unnecessary blockages, MIGS proves to be an effective method for controlling intraocular pressure.

MIGS is less invasive than traditional methods such as trabeculectomy or aqueous shunt surgery, reducing risk and ensuring a faster recovery for patients. MIGS is typically advised for individuals experiencing mild to moderate glaucoma with compromised drainage of fluid in the eye.

Mahmoud Rabie, Clinical Director for Ophthalmology and Consultant Ophthalmologist for CHEC, said: “At CHEC, we recognise the importance of empowering our patients with knowledge about their treatment options. MIGS procedures are known for their minimally invasive nature, utilising tiny incisions and advanced technology to enhance fluid drainage from the eye. Managing glaucoma can be a significant aspect of a person’s health journey, but MIGS provides a crucial solution to help prevent the progression of the disease and in turn, save the health of the optic nerve. It also has the potential to simplify postoperative care – as the eye’s natural drainage system is restored so quickly after surgery – and reduce the need for glaucoma eye drops. We’re excited about expanding the delivery of MIGS services on behalf of the NHS to more of our hospitals, bringing advanced treatment to a broader community to improve patient outcomes and quality of life.“